Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease

Brain

Volumn 138, Issue 9, 2015, Pages 2659-2671

  Locascio, Joseph J ^a,b   Eberly, Shirley ^c   Liao, Zhixiang ^a   Liu, Ganqiang ^a   Hoesing, Ashley N ^a,d   Duong, Karen ^a,d   Trisini Lipsanopoulos, Ana ^a,d   Dhima, Kaltra ^a,d   Hung, Albert Y ^b   Flaherty, Alice W ^b   Schwarzschild, Michael A ^b   Hayes, Michael T ^a   Wills, Anne Marie ^b,d   Shivraj Sohur, U ^b   Mejia, Nicte I ^b   Selkoe, Dennis J ^a   Oakes, David ^c   Shoulson, Ira ^e   Dong, Xianjun ^a   Marek, Ken ^f   Zheng, Bin ^a   Ivinson, Adrian ^a,d   Hyman, Bradley T ^b,d   Growdon, John H ^b   Sudarsky, Lewis R ^a   Schlossmacher, Michael G ^g   Ravina, Bernard ^h   Scherzer, Clemens R ^a,b,d   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d The Harvard Center for Neurodegeneration & Repair   (United States)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^g OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^h VOYAGER THERAPEUTICS   (United States)

Author keywords

biobank; biomarker; cognitive decline; gene expression; mitochondria; synuclein

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; DOPAMINE TRANSPORTER; MESSENGER RNA; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; TROPANE DERIVATIVE;

AGED; ARTICLE; BLOOD CELL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC RISK; GENETIC TRANSCRIPTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; NEUROIMAGING; PARKINSON DISEASE; PREDICTOR VARIABLE; PRIORITY JOURNAL; BLOOD; COGNITION DISORDERS; COMPLICATION; GENE EXPRESSION REGULATION; GENETIC SCREENING; GENETICS; METABOLISM; MICROARRAY ANALYSIS; MIDDLE AGED; PATHOLOGY; SCINTISCANNING; SEVERITY OF ILLNESS INDEX;

AGED; ALPHA-SYNUCLEIN; COGNITION DISORDERS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GENE EXPRESSION REGULATION; GENETIC TESTING; HUMANS; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NEUROIMAGING; PARKINSON DISEASE; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TROPANES;

EID: 84940759181     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv202     Document Type: Article

References (48)

1. Andreassi C, Riccio A. To localize or not to localize: mRNA fate is in 3'UTR ends. Trends Cell Biol 2009; 19: 465-74.
2. Auer H, Lyianarachchi S, Newsom D, Klisovic MI, Marcucci G, Kornacker K. Chipping away at the chip bias: RNA degradation in microarray analysis. Nat Genet 2003; 35: 292-3.
3. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002; 249 (Suppl 3): III/1-5.
4. Chahine LM, Stern MB, Chen-Plotkin A. Blood-based biomarkers for Parkinson's disease. Parkinsonism Relat Disord 2014; 20 (Suppl 1): S99-103.
5. Chen-Plotkin AS. Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron 2014; 84: 594-607.
6. Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol 2011; 69: 655-63.
7. Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat Med 2011; 17: 297-303.
8. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.
9. Neurology 2007; 68: 384-6.
10. Forman MS, Lee VM, Trojanowski JQ. Nosology of Parkinson's disease: looking for the way out of a quagmire. Neuron 2005; 47: 479-82.
11. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008; 26: 317-25.
12. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 2006; 5: 228-34.
13. Hayashi K, Masuda S, Kimura H. Impact of biomarker usage on oncology drug development. J Clin Pharm Ther 2013; 38: 62-7.
14. Hedeker D, Gibbons RD. Longitudinal data analysis. Hoboken, NJ: Wiley; 2006.
15. Hennecke G, Scherzer CR. RNA biomarkers of Parkinson's disease: developing tools for novel therapies. Biomark Med 2008; 2: 41-53.
16. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
17. Imbeaud S, Graudens E, Boulanger V, Barlet X, Zaborski P, Eveno E, et al. Towards standardization of RNA quality assessment using user-independent classifiers of microcapillary electrophoresis traces. Nucleic Acids Res 2005; 33: e56.
18. Jellinger KA. Synuclein deposition and non-motor symptoms in Parkinson disease. J Neurol Sci 2011; 310: 107-11.
19. Kasten M, Tadic V, Klein C, Rocca WA, Savica R, Eric Ahlskog J, et al. Anemia or low hemoglobin levels preceding Parkinson disease: A case-control study. Neurology 2010; 74: 1655; author reply 1656.
20. Kim JH, Jin HO, Park JA, Chang YH, Hong YJ, Lee JK. Comparison of three different kits for extraction of high-quality RNA from frozen blood. Springerplus 2014; 3: 76.
21. Locascio JJ, Atri A. An overview of longitudinal data analysis methods for neurological research. Dement Geriatr Cogn Dis Extra 2011; 1: 330-57.
22. Logroscino G, Chen H, Wing A, Ascherio A. Blood donations, iron stores, and risk of Parkinson's disease. Mov Disord 2006; 21: 835-8.
23. Maitta RW, Wolgast LR, Wang Q, Zhang H, Bhattacharyya P, Gong JZ, et al. Alpha-and beta-synucleins are new diagnostic tools for acute erythroid leukemia and acute megakaryoblastic leukemia. Am J Hematol 2011; 86: 230-4.
24. Malkov VA, Serikawa KA, Balantac N, Watters J, Geiss G, Mashadi-Hossein A, et al. Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter Assay System. BMC Res Notes 2009; 2: 80.
25. Manolio T. Novel risk markers and clinical practice. N Engl J Med 2003; 349: 1587-9.
26. Maroteaux L, Campanelli JT, Scheller RH. Synuclein: A neuronspecific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 1988; 8: 2804-15.
27. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: A cohort study. Lancet Neurol 2011; 10: 230-40.
28. Mollenhauer B, Rochester L, Chen-Plotkin A, Brooks D. What can biomarkers tell us about cognition in Parkinson's disease? Mov Disord 2014; 29: 622-33.
29. Murray IV, Giasson BI, Quinn SM, Koppaka V, Axelsen PH, Ischiropoulos H, et al. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 2003; 42: 8530-40.
30. Nakai M, Fujita M, Waragai M, Sugama S, Wei J, Akatsu H, et al. Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson's disease, in erythropoietic lineage. Biochem Biophys Res Commun 2007; 358: 104-10.
31. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 2014; 46: 989-93.
32. O'Brien JA, Ward A, Michels SL, Tzivelekis S, Brandt NJ. Economic burden associated with Parkinson disease. Drug Benefit Trends 2009; 21: 179-90.
33. Pahl A, Brune K. Gene expression changes in blood after phlebotomy: implications for gene expression profiling. Blood 2002a; 100: 1094-5.
34. Pahl A, Brune K. Stabilization of gene expression profiles in blood after phlebotomy. Clin Chem 2002b; 48: 2251-3.
35. Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011; 95: 629-35.
36. Rainen L, Oelmueller U, Jurgensen S, Wyrich R, Ballas C, Schram J, et al. Stabilization of mRNA expression in whole blood samples. Clin Chem 2002; 48: 1883-90.
37. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004; 4: 309-14.
38. Ransohoff DF. Bias as a threat to the validity of cancer molecularmarker research. Nat Rev Cancer 2005; 5: 142-9.
39. Rhinn H, Qiang L, Yamashita T, Rhee D, Zolin A, Vanti W, et al. Alternative alpha-synuclein transcript usage as a convergent mechanism in Parkinson's disease pathology. Nat Commun 2012; 3: 1084.
40. Rhodes SL, Ritz B. Genetics of iron regulation and the possible role of iron in Parkinson's disease. Neurobiol Dis 2008; 32: 183-95.
41. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
42. Savica R, Grossardt BR, Carlin JM, Icen M, Bower JH, Ahlskog JE, et al. Anemia or low hemoglobin levels preceding Parkinson disease: A case-control study. Neurology 2009; 73: 1381-7.
43. Scherzer CR, Feany MB. Yeast genetics targets lipids in Parkinson's disease. Trends Genet 2004; 20: 273-7.
44. Scherzer CR, Grass JA, Liao Z, Pepivani I, Zheng B, Eklund AC, et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci USA 2008; 105: 10907-12.
45. Scherzer CR, Jensen RV, Gullans SR. Simplifying complex neurodegenerative diseases by gene chip analysis. In: Freese A, Simeone FA, Leone P, Janson C, editors. Principles of molecular neurosurgery. Basel: Karger; 2004. p. 246-57.
46. Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 2011; 144: 689-702.
47. Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010; 75: 1055-61.
48. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2010; 2: 52ra73.